VIR Q2 2025 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena

VIRVir Biotechnology, Inc.

$1B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M-60.5% YoY

Gross Profit

-$96M-7932.9% margin

Operating Income

-$118M-9754.3% margin

Net Income

-$111M-9139.9% margin

EPS (Diluted)

$-0.80

QoQ Revenue Growth

-60.0%

Cash Flow

Operating Cash Flow

-$120M

Free Cash Flow

-$123M

Stock-Based Comp.

$12M

Balance Sheet

Total Assets

$1.2B

Total Liabilities

$245M

Stockholders' Equity

$947M

Cash & Equivalents

$211M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$3M	-60.5%
Gross Profit	-$96M	-$102M	+5.7%
Operating Income	-$118M	-$159M	+25.4%
Net Income	-$111M	-$138M	+19.8%

Revenue Segments

Contract Revenue

$2M89%

Grant

$183,00011%

Geographic Segments

Non-US

$2M89%

UNITED STATES

$183,00011%